Exenatide News and Research RSS Feed - Exenatide News and Research

Exenatide (marketed as Byetta) is one of a new class of medications (incretin mimetics) approved for the treatment of diabetes mellitus type 2.
FDA clears Oramed Pharmaceuticals' IND for ORMD-0801

FDA clears Oramed Pharmaceuticals' IND for ORMD-0801

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration has cleared the Company's Investigational New Drug application for ORMD-0801, its oral insulin capsule. [More]
Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

Acute pancreatitis is an inflammation of the pancreas which leads to leakage of pancreatic enzymes. Apart from certain drugs such as GLP-1 based therapies, the most common causes of pancreatitis are Gallstones and Alcohol use. [More]

Oramed to report results of T1DM oral insulin formulation at Diabetes Summit 2013

Oramed Pharmaceuticals Inc., a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013. [More]

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Eli Lilly and Company today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes. [More]

Oramed Pharmaceuticals receives Japanese patent for innovative oral delivery technology

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the Japanese Patent Office. [More]
New study associates commonly used diabetes drugs with pancreatic cancer risk

New study associates commonly used diabetes drugs with pancreatic cancer risk

ndividuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine tumors, according to a new study by researchers from UCLA and the University of Florida. [More]
GLP-1 pancreatitis concerns justified

GLP-1 pancreatitis concerns justified

Study results have raised further concerns over a link between pancreatitis and the use of glucagon-like peptide-1 (GLP-1)-based therapies for patients with Type 2 diabetes. [More]
GLP-1 may increase risk of hospitalization for people with acute pancreatitis

GLP-1 may increase risk of hospitalization for people with acute pancreatitis

People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report. [More]

Oramed to submit new oral insulin IND with FDA

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has been in communication with the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application for oral insulin. [More]

GLP-1 receptor agonists associated with reduced BMI in adolescents with severe obesity

Preliminary evidence from a clinical trial suggests that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced body mass index and body weight in adolescents with severe obesity, according to a report published Online First by JAMA Pediatrics, a JAMA Network publication. [More]

Oramed files IND with FDA to begin ORMD-0801 Phase 2 trial for type 2 diabetes

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its orally ingested insulin candidate, ORMD-0801. [More]
EU approves Forxiga for treatment of type 2 diabetes

EU approves Forxiga for treatment of type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes. [More]
Results from liraglutide and exenatide head-to-head comparison trial on type 2 diabetes

Results from liraglutide and exenatide head-to-head comparison trial on type 2 diabetes

A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded mixed results. [More]
Diabetes drug could treat illicit drug addiction

Diabetes drug could treat illicit drug addiction

Researchers have found that a drug currently used to treat Type 2 diabetes could treat addiction to drugs such as cocaine. [More]

Intarcia announces results from ITCA 650 phase 2 study on type 2 diabetes

Intarcia Therapeutics, Inc. announced that an analysis of the results of a phase 2 clinical study of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes will be presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany on Wednesday, October 3, 2012. [More]

Extended release exenatide outperforms twice daily regimen

Once-weekly extended-release exenatide is a more effective treatment than twice-daily exenatide at improving glucose control among Japanese individuals with diabetes, report researchers. [More]

Bristol-Myers Squibb completes acquisition of Amylin

Bristol-Myers Squibb Company and AstraZeneca announced that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals, now a wholly-owned subsidiary of Bristol-Myers Squibb. [More]
Scientists identify mechanisms by which GLP-1 protects against kidney disease, diabetes

Scientists identify mechanisms by which GLP-1 protects against kidney disease, diabetes

Scientists at Joslin Diabetes Center have identified biological mechanisms by which glucagon-like peptide-1 (GLP-1), a gut hormone, protects against kidney disease, and also mechanisms that inhibit its actions in diabetes. [More]

Bristol-Myers Squibb to acquire Amylin

Bristol-Myers Squibb Company and Amylin Pharmaceuticals, Inc. announced today that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion. [More]

Exenatide ‑ a better alternative for add-on therapy?

Twice-daily exenatide may offer advantages over the standard glimepiride in patients with Type 2 diabetes inadequately controlled by metformin, suggest findings published in The Lancet. [More]